Indegene

Last updated

Indegene Limited
FormerlyIndegene Lifesystems Private Limited (1998–2016)
Indegene Private Limited (2016–2022)
Company type Public
Industry
Founded1998;26 years ago (1998)
FoundersRajesh Nair
Manish Gupta
Sanjay Parikh
Anand Kiran
Gaurav Kapoor
Headquarters
Bangalore
,
India
Area served
Worldwide
Key people
Manish Gupta (CEO) [1]
RevenueIncrease2.svg₹2,589 crore (US$310 million) (FY24) [2]
Increase2.svg₹584 crore (US$70 million) (FY24) [2]
Increase2.svg₹336 crore (US$40 million) (FY24) [2]
Owners
Number of employees
5,081 (March 2024) [2]
Website www.indegene.com

Indegene Limited is an Indian company that provides research and commercialization services to biopharmaceutical and healthcare enterprises. [4] [5] [6] Based in Bangalore, the company specializes in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics. [7] [8]

Contents

History

Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran. [9] Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under the same name in the United States. [10] In 2008, Medsn officially became known as Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a continuing medical education company based in the United States. [6] [11]

In 2009, Indegene signed a master service agreement with six pharmaceutical companies. [5] [12] The following year, Indegene acquired Canada-based Aptilon, a multichannel marketing firm, for $4 million. [13] The company subsequently acquired Atlanta-based Total Therapeutic Management in 2014. [14]

In September 2019, Indegene acquired London-based consulting company, DT Associates, for $10 million. [15]

In February 2021, the Carlyle Group and Brighton Park Capital invested $200 million in Indegene. [16] In August 2021, Indegene acquired Medical Marketing Economics (MME), an American market access and pricing strategy company, for $10 million. [17]

Indegene went public in May 2024 with an initial public offering, raising ₹1,842 crore (US$220 million). It listed on the BSE and the NSE. [18]

Operations

Indegene has offices in India, the United States, the European Union, and Asia-Pacific. [19] [11]

In 2011 and 2012, The Economic Times named Indegene one of the best companies to work for in the Professional Services industry. [20]

See also

Related Research Articles

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.

<span class="mw-page-title-main">Warburg Pincus</span> New York private equity firm

Warburg Pincus LLC is a global private equity firm, headquartered in New York City, with offices in the United States, Europe, Brazil, China, Southeast Asia and India. Warburg has been a private equity investor since 1966. As of October 2023 the firm had over $82 billion in assets under management and invests in a range of sectors including retail, industrial manufacturing, energy, financial services, health care, technology, media, and real estate. Warburg Pincus is a growth investor. Warburg Pincus has raised 21 private equity funds which have invested over $100 billion in over 1,000 companies in 40 countries.

<span class="mw-page-title-main">Otsuka Pharmaceutical</span> Japanese pharmaceutical company

Otsuka Pharmaceutical Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

IMS Health was an American company that provided information, services and technology for the healthcare industry. IMS stood for Intercontinental Medical Statistics. It was the largest vendor of U.S. physician prescribing data. IMS Health was founded in 1954 by Bill Frohlich and David Dubow with Arthur Sackler having a hidden ownership stake. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners. The company went public on April 4, 2014, and began trading on the NYSE under the symbol IMS. IMS Health was headquartered in Danbury, Connecticut.

Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. The company publishes the annual Parexel R&D Statistical Sourcebook and operates the Parexel-Academy.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

Snyder Communications Inc. (SNC) was an American advertising corporation founded in 1988 by Daniel Snyder and his sister Michelle Snyder. Their activities were mainly outsourced marketing services, such as direct marketing, database marketing, proprietary product sampling, sponsored information display in prime locations, call centers, and field sales.

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

IQVIA, formerly Quintiles and IMS Health, Inc., is an American Fortune 500 and S&P 500 multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development, professional consulting and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including investment strategy and management consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of US$49 billion as of August 2021. As of 2023, IQVIA was reported to be one of the world's largest contract research organizations (CRO).

<span class="mw-page-title-main">Tata Technologies</span> Indian engineering services company

Tata Technologies Limited is an Indian multinational product engineering company that provides services in engineering and design, product lifecycle management, manufacturing, product development, and IT service management to automotive and aerospace original equipment manufacturers as well as industrial machinery companies. It is a subsidiary of Tata Motors.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

<span class="mw-page-title-main">Nimmagadda Prasad</span> Indian businessman

Nimmagadda Prasad is an Indian industrialist from Andhra Pradesh, India. He is known for his ventures in the Pharmaceutical and Television industries, and is involved in philanthropic activities through Nimmagadda Foundation.

Flipkart Private Limited is an Indian e-commerce company, headquartered in Bangalore, and incorporated in Singapore as a private limited company. The company initially focused on online book sales before expanding into other product categories such as consumer electronics, fashion, home essentials, groceries, and lifestyle products.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Mankind Pharma</span> Indian pharmaceutical and healthcare products company

Mankind Pharma is an Indian pharmaceutical and healthcare products company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

OYO Rooms, also known as OYO Hotels & Homes, is an Indian multinational hospitality chain of leased and franchised hotels, homes, and living spaces. Founded in 2012 by Ritesh Agarwal, OYO initially consisted mainly of budget hotels. As of January 2020, it has more than 43,000 properties and 1 million rooms across 800 cities in 80 countries.

Nykaa is an Indian e-commerce company headquartered in Mumbai. It sells beauty, wellness and fashion products through its website, mobile app, and over 100 physical stores. In 2020, it became the first Indian unicorn startup headed by a woman.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

References

  1. ↑ "Indegene on the prowl for global acquisitions". The Hindu Businessline. 12 August 2020. Retrieved 8 January 2023.
  2. 1 2 3 4 "Fact Sheet – Q4 FY2024" (PDF). Indegene. Retrieved 30 May 2024.
  3. ↑ "PE firms Carlyle, Nadathur Fareast, Brighton Park Capital-backed Indegene IPO to open on May 6". Moneycontrol. Retrieved 28 April 2024.
  4. ↑ Das, Avik (2 September 2015). "Flipkart, Practo CEOs get top rating from staff". The Economic Times . Retrieved 2 October 2015.
  5. 1 2 Singh, Seema (7 May 2009). "Cutting pharma costs by intelligent marketing". Mint . Retrieved 2 October 2015.
  6. 1 2 Unnikrishnan, CH (8 November 2006). "Indegene buys US firm". Business Standard . Retrieved 2 October 2015.
  7. ↑ Murayama, Keiichi (19 February 2015). "India's tech muscle has the world's attention". The Nikkei . Retrieved 2 October 2015.
  8. ↑ "Indegene files papers with Sebi; eyes ₹3,200 crore via IPO". mint. 15 December 2022. Retrieved 8 January 2023.
  9. ↑ Amirapu, Deepika (9 March 2012). "Indegene eyes US call centre buy for $10–15 million". The Economic Times . Retrieved 2 October 2015.
  10. ↑ D'Silva, Jeetha (17 September 2005). "Indegene acquires US medical education co". The Economic Times . Retrieved 2 October 2015.
  11. 1 2 "Indegene acquires MedCases, LLC". NFV Zone. 30 November 2006. Retrieved 2 October 2015.
  12. ↑ "Indegene highlights benefits of patient adherence programs for pharma cos". PharmaBiz. 3 June 2011. Retrieved 2 October 2015.
  13. ↑ Mukherjee, Rupali (7 November 2012). "Indegene to acquire Canada-based company for $4 million". Times of India . Retrieved 2 October 2015.
  14. ↑ Craig, Tara (9 January 2014). "Indegene acquires Total Therapeutic Management". PMLive.com. Retrieved 2 October 2015.
  15. ↑ Balakrishnan, Reghu (3 September 2019). "Healthcare tech firm Indegene acquires DT Associates". The Economic Times. Retrieved 28 April 2024.
  16. ↑ Madhurima, Nandy (3 February 2021). "Indegene to raise $200 mn from Carlyle, Brighton Park". LiveMint . Retrieved 20 August 2021.
  17. ↑ Baruah, Ayushman (30 August 2021). "Indegene acquires US-based Medical Marketing Economics for $10 mn". Mint. Retrieved 28 April 2024.
  18. ↑ Narayanan, KS Badri (6 May 2024). "Indegene IPO opens today in ₹430-452 price band". BusinessLine. Retrieved 6 May 2024.
  19. ↑ Vijay, Nandita (7 November 2012). "Indegene plans next phase of growth through acquisition in US, EU markets". PharmaBiz. Retrieved 2 October 2015.
  20. ↑ "Best companies to work for 2012: Companies that came up trumps across various sectors". The Economic Times . 16 July 2012. Retrieved 2 October 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.